Sold as Resniben. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 15, 2026, FDA lists 3 applications for Cabozantinib (sold as Resniben), with 0 new uses approved and 0 published complete response letters.
| Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to RelapseOsteosarcoma, Pediatric Osteosarcoma · Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 | Recruiting | Oct 13, 2026 |
| First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainRenal Cell Carcinoma (RCC) · Bristol-Myers Squibb | — | Active, not recruiting | Oct 1, 2026 |
| A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)Clear Cell Renal Cell Carcinoma (ccRCC) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 1 | Not yet recruiting | Sep 30, 2026 |
| Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell CarcinomaRenal Cell Carcinoma · Centro di Riferimento Oncologico - Aviano | Not applicable | Recruiting | Sep 4, 2026 |
| A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) PatientsGastroenteropancreatic Neuroendocrine Tumor · Novartis Pharmaceuticals | — | Recruiting | Jun 9, 2026 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyCancer, Renal Cell Carcinoma (RCC) · Exelixis | Phase 3 | Enrolling by invitation | Jun 2, 2026 |
| Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)Von Hippel-Lindau Disease, Malignant Neoplasms · Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Feb 12, 2026 |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerAdvanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma · SWOG Cancer Research Network | Phase 3 | Recruiting | Feb 3, 2026 |
| — | CabozantinibANDA 215942 | Teva Pharms Inc | 0 | Marketed |
| — | CabozantinibANDA 220121 | Biocon Pharma Limited | 0 | Discontinued |
| — | ResnibenNDA 220258 | Azurity | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA